# Cardinal Health Inc: Form 10-Q for the period ended Dec 31, 2023

- Company: [Cardinal Health Inc](/companies/cah.md) (CIK 721371)
- Form: 10-Q
- Filed: 2024-02-01
- Accepted by EDGAR: Feb 1, 2024, 13:54 ET
- Period: 2023-12-31
- Accession: 0001628280-24-002813
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/721371/000162828024002813/cah-20231231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/721371/000162828024002813/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-10-01 to 2023-12-31 | $57.45bn | us-gaap:Revenues |
| Revenue | 6 months, 2023-07-01 to 2023-12-31 | $112.21bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2023-10-01 to 2023-12-31 | $55.60bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2023-07-01 to 2023-12-31 | $108.59bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2023-10-01 to 2023-12-31 | $1.85bn | us-gaap:GrossProfit |
| Gross profit | 6 months, 2023-07-01 to 2023-12-31 | $3.61bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2023-10-01 to 2023-12-31 | $1.28bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2023-07-01 to 2023-12-31 | $2.48bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2023-10-01 to 2023-12-31 | $482.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2023-07-01 to 2023-12-31 | $468.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-10-01 to 2023-12-31 | $8.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2023-07-01 to 2023-12-31 | $22.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-10-01 to 2023-12-31 | $136.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2023-07-01 to 2023-12-31 | $104.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-10-01 to 2023-12-31 | $353.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2023-07-01 to 2023-12-31 | $358.0m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months, 2023-10-01 to 2023-12-31 | 246,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2023-07-01 to 2023-12-31 | 248,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2023-07-01 to 2023-12-31 | $1.73bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2023-07-01 to 2023-12-31 | $206.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2023-07-01 to 2023-12-31 | $255.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2023-07-01 to 2023-12-31 | $750.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2023-12-31 | $4.59bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-12-31 | $37.66bn | us-gaap:AssetsCurrent |
| Total assets | at 2023-12-31 | $46.57bn | us-gaap:Assets |
| Current liabilities | at 2023-12-31 | $38.29bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2023-12-31 | −$3.45bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/721371/000162828024002813/cah-20231231.htm

Filed Feb 1, 2024.
Source: SEC EDGAR, the filing index for accession 0001628280-24-002813. Last ingested by Listed: Oct 24, 2026, 14:55 ET. No prices; not investment advice.